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The rapid advance of the coronavirus COVID-19 pandemic has significantly increased mortality but also has 
demonstrated considerable potential to negatively impact mental health, including in the young
1,2
.  From a 
public mental health perspective, guidelines for responding to mass trauma and disaster emphasize the 
importance of focusing on resilience.  In the immediate and ongoing response, consensus guidelines emphasize 




That said, it is important to provide appropriate attention to specific psychiatric conditions that may be initiated 
or exacerbated by disaster. Perhaps no group of individuals with mental illness is as directly affected by the 
worsening outbreak of COVID-19 as people living with obsessive-compulsive disorder (OCD). Paradoxically, 
they are ‘experts by experience’ in attempting to avert dangers through enacting compulsive behaviours. 
Chiefly, the spike in anxiety about the virus is fuelling existing obsessive fears of contamination in some people 
with OCD and further triggering harmful compulsive actions. For these people, coronavirus can become all they 
think about 
5. Indeed, some patients with contamination-related OCD are expressing doubts about the rationality 
of the therapies they have been pursuing.  Several patients have told their clinicians they were “right all along”, 
as now everybody looks like them. For others, COVID-19 is likely to cast a long shadow, as people of all ages 
with OCD are known to be particularly inflexible at ‘unlearning’ danger responses when they become 
obsolete
6,7 
and thereby conditioned to prolonged virus-induced distress and anxiety.  
In response to the emerging crisis and growing calls from patients and clinicians for guidance
 5
, a working group 
of clinical experts from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and 
the Obsessive-Compulsive Research Network of the European College of Neuropsychopharmacology (OCRN) 
have produced this consensus statement with the aim of delivering pragmatic guidance at the earliest 
opportunity to clinicians for managing this complex challenge.  
The advice is largely based on empirical evidence, including the clinical experience gained from working in 
specialised OCD treatment-services before and during the pandemic. Our group of international experts includes 
a balanced representation of genders, including clinicians treating child, adolescent and adult patients, with 
additional contributions from individuals with lived experience of the disorder and early career scientists.  Once 
agreement was reached on the key issues to be covered, in a series of online discussions, an initial draft was 
prepared and circulated iteratively among the authors and edits were sequentially incorporated. The final report 
covers the key issues judged by our group of experts to be of most relevance for clinicians for the treatment of 
OCD under COVID-19 conditions. Although preliminary, based on the ‘precautionary principle’ it was 
considered a priority to release guidance at the earliest opportunity, on the understanding that it may be updated 
as new information arises.  
The guidance to clinicians is as follows: 
1. Take a compassionate calming approach. Use telemedicine including telephone or video calls. Be aware that 
the pandemic is affecting countries with different cultural environments and different available resources to deal 
with it.  For example, in regions of Latin América and in Africa lack of water and access to the Internet, and 
poverty levels greater than 50 % make it hard to stay in at home, since there is no monetary support from the 










2. Careful history taking. Confirm the diagnosis of OCD, paying particular attention to other obsessive-
compulsive related disorders (OCRDs) including hypochondriasis (recently endorsed as an OCRD in the World 
Health Organisation (WHO) ICD-11)
8
, as these disorders are likely to be most affected by COVID-19. Clarify 
the extent to which the current symptoms represent a rational or exaggerated reaction to recent highly stressful 
events, or a worsening of obsessive-compulsive symptomatology. Establish the level of insight into the 
irrationality or excessiveness of the symptoms, and the presence or absence of tics, as these may influence the 
care plan. Note that many OCD patients may not experience exacerbation of their OCD. On the other hand, 
patients who have experienced contamination symptoms in the past may find that they re-experience 
contamination fears and cleaning or washing compulsions under the conditions of the pandemic.  It is also 
important not to assume that every patient with contamination fears related to germs and illness will necessarily 
be excessively concerned about COVID-19. The focus of concerns in those with OCD is often idiosyncratic, and 
some individuals, for example, may have greater fears of a sexually transmitted disease or an antibiotic resistant 
infection. Many will, however, have significant exacerbation of contamination or illness concerns, or comorbid 
conditions that have worsened with stress (such as anxiety disorder, depression or bipolar disorder, or even post-
traumatic stress disorder (as reported after the SARS epidemic) that may need to be managed separately in order 
to prevent decline in level of functioning. Indeed, OCD comorbidity can become particularly problematic, 
especially if patients have, or have previously shown, cleaning or washing symptoms. Where OCD and related 
disorder is not the principal diagnosis for clinical attention, please refer to other guidelines.  In particular, note 




3.  Assess suicidal risk. Even though OCD has not been considered a disorder with high risk for suicide, recent 
studies have shown that some patients, particularly those with severe obsessions, comorbid depression, bipolar 
disorder, impulse control disorders, substance use disorders, personality and eating disorders may be at 
increased risk 
9
. Additional COVID-related factors found anecdotally to potentially increase suicidal risk 
include a recent increase in OCD severity, experiencing a family member found positive for COVID-19 or 
finding the effects of quarantine or isolation distressing. For all patients with OCD, but particularly in such 
cases, consider actively evaluating the suicide ideation and risk through specific questions and instruments (e.g., 
the Columbia Suicide Severity Rating Scale 
10
 or similar) and hospitalize the patient if needed. 
4. Provide psychoeducation with balanced information about the known risks and impact of COVID-19 on 
physical and mental health. This includes the difficulties managing uncertainty associated with the virus, which 
almost everyone is experiencing right now but that might be particularly challenging for some people with 
OCD, hypochondriasis or anxiety. Highlight the need for physical distancing (staying home except for essential 
tasks like grocery shopping), with special precautions for the elderly. Patients need to understand that this health 
crisis may well persist for some time, and they need to manage their stress levels over time (e.g., by putting into 
play long-term routines of mindfulness techniques, exercise and structure). 
5. Enquire about Internet usage and news consumption; some patients are spending hours a day watching 
television and online media sources, which may be significantly exacerbating their OCD and anxiety. Offer a 
balanced approach (e.g., individuals should not spend more than an hour a day [1/2 hour in the morning and a 










trusted sources to avoid myths, rumors and misinformation. You may wish to refer the patient to the relevant 
health education websites of the WHO (https://www.who.int/health-topics/coronavirus#tab=tab_1), the Centers 
for Disease Control and Prevention (CDC) (https://www.cdc.gov/coronavirus/2019-ncov/infection-control/hcp-
hand-sanitizer.html), or the Center for Health Security, Johns Hopkins University 
(http://www.centerforhealthsecurity.org/resources/COVID-19/index.html). Handwashing videos may be helpful 
to guide patients about what is appropriate and discourage unnecessary excess. For example, the National Health 
Service (https://www.nhs.uk/video/pages/how-to-wash-hands.aspx) and CDC videos 
https://www.youtube.com/watch?v=3EoAyQu3LIs) recommend handwashing for 20 seconds; thus, anything 
beyond this is likely to be compulsive and excessive.  
6. If OCD symptoms are the main problem:  
I. Review medication status as a priority; Based on the risks associated with exposure and response prevention 
(ERP) in the pandemic (see below), and uncertainty as to which of the two evidence-based treatments, 
pharmacotherapy or cognitive behaviour therapy (CBT), represents the most efficacious first line treatment 
modality
11
,  pharmacotherapy should be the first option for adults and children with OCD  with contamination, 
washing or cleaning  symptoms during the COVID-19 pandemic. Consider A) type of medication; most patients 
should receive an SSRI, or if not responsive, another SSRI and as a third choice clomipramine (for which an 
ECG may be required in certain patient groups); B) dosage; if the patient is on a suboptimal dose, consider 
increasing it, paying attention to any contraindications; C) SSRI-resistance; consider low dose of adjunctive 
antipsychotic (aripiprazole, risperidone, quetiapine, olanzapine), especially if a tic is present; D) adherence; 
ensure the patient is able to obtain an adequate supply and is taking the treatment regularly. In cases where 
adherence is problematic, especially if insight is poor or there are executive dysfunction deficits, it may be 
necessary to provide additional support either from clinical support staff or the family to ensure adherence. The 
use of Medi Pill Organisers (dosette boxes) and tools such medisafe (free application that aids patients to 
remember to take medications and sends reports to the psychiatrists) can be helpful to monitor adherence; E) 
manage sleep disturbance when present, as healthy sleep contributes to immune function and enhances anxiety 
management. 
II. Review and risk assess the CBT plan; Considerations include whether it is feasible in the pandemic situation, 
and specifically whether it fits with government safety guidance. In many countries, psychotherapy services are 
being dramatically cut back as staff are redeployed to cover emergency care. Consider that it can be difficult to 
disentangle OCD-related cleaning and checking compulsions from rational COVID-19-related safety behaviours 
and to devise ERP strategies that are coherent and robust. Moreover, as COVID-19 is highly contagious, and 
patients can easily be confused by exposure exercises, particularly during the early stages of therapy or when 
practising exposure on their own at home, the risk of patients becoming seriously infected with the coronavirus 
could be increased. This risk becomes even more true for children whose knowledge base and judgment is not 
yet matured.   
We therefore recommend significantly tailoring CBT to take into account the CDC guidance (e.g., hand washing 
for 20 seconds with soap and water rather than ceasing hand washing completely). However for OCD patients 
with contamination fears and cleaning or washing compulsions, active and in vivo CBT with exposure and 










to active, in vivo exposure aimed at tackling contamination. Instead we suggest using therapist time to support 
patients and trying to prevent them from deteriorating, e.g. by encouraging them to restrain their compulsions as 
far as possible, rather than directed at actively treating contamination fears and concentrating on techniques 
such as behavioural activation and activity scheduling which can assist in preventing deterioration and help with 
depressive symptoms
12
. Indeed, activity scheduling can be particularly useful as a form of CBT at this time. 
Obsessions often expand to fill a vacuum of time and keeping busy is particularly important as a means of 
staying well. Patients can be asked to fill out an activity schedule diary in advance, making sure that they have a 
balance between activities which may give them a feeling of mastery as well as those for pleasure (see below) 
13
. 
For clinicians working in specialist centres, other less  evidence-based forms of CBT not involving ERP, such as 
imaginal exposure or danger ideation reduction therapy, could potentially be offered for patients with 
contamination – related OCD, even when their concern is COVID. This should be considered on a case-by-case 
basis and only done if the patient has good insight, is willing, and is stable enough to do so. It would need to be 
made clear that the efficacy of this form of treatment is not as well established and it should not be viewed as a 
substitute for in vivo ERP when post pandemic restrictions are lifted.  
For those patients whose exposures are not contamination related, many ERP treatment plans could be 
continued (e.g. addressing urge to check, obsessive thoughts of harm, symmetry/order obsessions), especially 
those that can be done at home, and as long as they are within CDC recommended precautions such as 
maintaining physical distancing. Once again it is important to remember that even if the OCD does not focus on 
contamination fears, the physical distancing can increase symptoms of anxiety and depression. ERP increases 
distress and can also temporarily increase depression and so the patient’s mental state must be monitored 
carefully.   
Keeping people calm and reducing the risk of depression using supportive techniques is an essential element of 
care. Nevertheless, the clinician should still try to find ways to help the patient foster resilience towards 
obsessional thinking and compulsive acts. Thus, extreme behaviours should be discouraged along with mental 
compulsions. Avoidance and accommodation should be assessed carefully to determine whether it is 
proportional to the current situation and addressed carefully to prevent backsliding.  
We suggest therapists should regularly check e.g. by phone or digitally, those OCD patients likely to engage in 
particularly harmful decontamination rituals or behaviours. The use of video calls with the patients should be 
recommended, where possible. The added benefit of video calling is that it helps the therapist perform a visual 
risk evaluation, which is especially valuable for patients living alone, to determine the condition of the patient’s 
hands, presence of food in the fridge or cupboard, etc. One group of patients requiring particularly vigilant care 
are those who, as a result of doubt or uncertainty about whether food in the house is contaminated, respond by 
throwing everything away and consequently have little or no food in the house. Identify and discourage high-
risk obsessive-compulsive behaviours, such as washing in boiling (very hot) water or bleach, or total fasting. On 
the contrary, encourage eating and drinking to maintain health.  
III. Deep brain stimulation (DBS): For this small group with extremely severe, treatment resistant illness, a 
moderate increase of psychological distress or OCD symptoms may be expected during the pandemic, but this 










patients waiting for DBS until the outbreak is over. In those who have electrodes implanted, a worsening of 
OCD symptoms may be experienced if the battery stops working. Such patients should be encouraged to check 
with their treating clinician in case the power has simply been turned off, or if there is a real need for battery 
replacement. If the latter, a balance between risks and benefits should be evaluated in each case and 
consideration given to whether the replacement procedure may be delayed to reduce the increased risk of being 
exposed to COVID-19 in hospital. 
IV. Social and occupational care; There is great value in activity scheduling and establishing a daily routine, 
even if stuck at home. Patients under quarantine or staying at home under national restrictions are at great risk of 
circadian rhythm disruption. Circadian rhythms disruption could increase anxiety and worsen OCD symptoms 
while regular circadian rhythms and regular physical activity are relevant in order to reduce anxiety or alarm 
levels and therefore achieve better control of OCD symptoms. Therefore it is recommended to respect a regular 
awakening time and bedtime every day and to regularly perform some physical activity in the morning 
especially in a bright room. Finally it is recommended to avoid late-night dinners so as not to affect sleep 
quality.  
Offer guidance regarding a rational amount of time spent listening to news as a distraction to occupational or 
preferred activities, provide acknowledgement of fear but also a balanced perspective on risk, address grief and 
loss of control and recommend hedonic activities especially those that involve children, such as baking, 
cooking, gardening, inventing a new game or watching a movie.  
Help the isolated patient to overcome loneliness and build stability by increasing communication with friends, 
family members and loved ones, even if at a distance via the multiple online platforms including Facetime; 
Skype and Zoom. Learning to use these can be a helpful experience in terms of the acquisition and mastery of 
new skills as well as the pleasure of social contact. In the case of those with a poor social network, telephone 
helplines such as those run by OCD charities are particularly useful, especially if managed by qualified trained 
professionals.  
Also encourage patients and family members to keep weight under control e.g. by creating new places for sports 
in the home and including physical activity in their home routine. Exercise can be additionally helpful for some 
patients coping with the mental effects of the pandemic. Aerobic exercise has in some studies been shown to 




. Where there is ability to go out for 
aerobic exercise once a day then a brisk walk or run can be useful. Some excellent videos are available online 
(e.g. using home-based workout exercises that are freely available on YouTube or other mobile apps), 
demonstrating aerobic exercises that can be performed in a limited space. Gyms and yoga studios centers are 
fuelling the drive to stay active by offering online exercise classes, some free of charge, or extending trial 
periods for at-home workouts.  
V. Carer support; Remember that family members and caregivers of patients with OCD are also at increased risk 
of developing stress related disorders owing to the worsening of patients’ symptoms and may need additional 
support in their own right. Parents of children with OCD are likely to require even more coaching and support 
than before, especially as relationships may be impacted in unpredictable ways by the fact that parents and 
children are spending so much time together. Consider that parents are burdened differently under COVID-19, 










becoming irritable or aggressive (as is often the case for children with OCD if their behaviours are not 
accommodated). 
Parents and children should be encouraged to maintain social contact with their environment via the Internet or 
phone for distraction and support. Rules for dealing with possible conflicts and tantrums should ideally be 
established in advance. Parents should not only focus on the problems connected with the current pandemic 
situation but be encouraged to engage in joyful activities with their child instead. Especially in a quarantine 
situation it is important to make clear that not all aspects of life are determined by the coronavirus or OCD. 
Staying hopeful and together seems one of the most important points (especially for parents, acting as role 
models for their children), and increased family togetherness may be a “silver lining” in the pandemic. 
We are aware this guidance marks a change in practice for many clinicians treating OCD. Temporarily 
modifying or pausing in vivo CBT with ERP for contamination-related OCD, which is an effective form of 
treatment often preferred by patients in normal times, is a difficult decision to make, but as with any treatment, 
the benefits and risks need to be balanced up and clear messages that take public health into account need to be 
given at this time of heightened risk of infection, to avoid confusion. On the other hand, many forms of CBT can 
be continued with modification for safety as needed. We believe that under COVID-19, stringent efforts should 
be made to provide effective care for individuals with OCD and that the best available treatments for most 
patients are likely to include providing evidence-based pharmacotherapy and modifying or pausing CBT in 
conjunction with enhanced supportive therapies including social and occupational care. Understanding the 
impact of a pandemic like COVID-19 on the expression of OCD in affected patients, and on the development of 
new cases of OCD, is likely to provide important insights into the environmental determinants of the disorder. 
We consequently urge research-active groups to engage in investigating the impact of such changes on health 
outcomes among their patients, as well as initiatives to explore the expected rise in incidence of OCD once the 
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